Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study.

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. COPD results from chronic inflammation of the lungs. Current treatments, including physical and chemical therapies, provide limited results. Stem cells, particularly mesenchymal stem cells (MSCs), are used to treat COPD. Here, we evaluated the safety and efficacy of umbilical cord-derived (UC)-MSCs for treating COPD. METHODS: Twenty patients were enrolled, 9 at stage C and 11 at stage D per the Global Initiative for Obstructive Lung Disease (GOLD) classification. Patients were infused with 106 cells/kg of expanded allogeneic UC-MSCs. All patients were followed for 6 months after the first infusion. The treatment end-point included a comprehensive safety evaluation, pulmonary function testing (PFT), and quality-of-life indicators including questionnaires, the 6-min walk test (6MWT), and systemic inflammation assessments. All patients completed the full infusion and 6-month follow-up. RESULTS: No infusion-related toxicities, deaths, or severe adverse events occurred that were deemed related to UC-MSC administration. The UC-MSC-transplanted patients showed a significantly reduced Modified Medical Research Council score, COPD assessment test, and number of exacerbations. However, the forced expiratory volume in 1 s, C-reactive protein, and 6MWT values were nonsignificantly reduced after treatment (1, 3, and 6 months) compared with those before the treatment. CONCLUSION: Systemic UC-MSC administration appears to be safe in patients with moderate-to-severe COPD, can significantly improve their quality of life, and provides a basis for subsequent cell therapy investigations. TRIAL REGISTRATION: ISRCTN, ISRCTN70443938. Registered 06 July 2019.

Endoscopic and histopathological characteristics of bronchial asthma out of the outbreak crisis

From June 2001 to June 2002, in the Hospital 103, 31 patients aged 16-75 were studied. In 100% of them, brochial endoscopy found the contraction of bronchi under direct mechanical stimuli of the end edge of the endoscopy. This mild contraction flashed and self terminated. Out of the outbreak crisis, in 100% of bronchial biopsy samples, inflammation image appeared, and the bronchial structure changed. The main histopathological exhibitions were the infiltration of essinophile white blood, enlarging of bronchi and of the smooth muscle, the hypertrophy of bronchial epithelia and fibrosis under bronchial epithelia

Paraneoplastic syndrome in bronchal cancer

Study was carried out in 162 bronchial cancer patients (83 males, 75 females) in National Institute of Tuberculosis and Lung Diseases from November 1991 to October 1994. Paraneoplastic syndrome account for 51.8% including the symptoms of bone-articular and connective tissues, 43.6% hematology 22.8%, skin 6.8%, endocrino-metabolism 3.1% and kidney 0.6%. Paraneoplastic syndromes of bone-articular connective tissue, include pain manifestations of bones and joints, finger clubbed, symptoms of hematology: anemia, neutrophilia, eosiniphilia and polyplastocytosis; symptoms of skin: hypertrichosis, keratodermia, chloasma cutaneous dystrophy in two feet, vascularmotrice disturbance of inferior limbs; symptoms endocrino-metabolism: hyperuricemia, inaddition, there are some manifestations on kidney and chronical glomerulo-nephritis